Page 995 - Read Online

Page 16 of 18 Machado. Hepatoma Res 2020;6:84 I http://dx.doi.org/10.20517/2394-5079.2020.90

Hepatol 2017;66:123-31.
83. Petta S, Ciminnisi S, Di Marco V, et al. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver
disease. Aliment Pharmacol Ther 2017;45:510-8.
84. Yu R, Shi Q, Liu L, Chen L. Relationship of sarcopenia with steatohepatitis and advanced liver fibrosis in non-alcoholic fatty liver
disease: a meta-analysis. BMC Gastroenterol 2018;18:51.
85. Cai C, Song X, Chen Y, Chen X, Yu C. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a
systematic review and meta-analysis. Hepatol Int 2020;14:115-26.
86. Tobari M, Hashimoto E, Taniai M, et al. Characteristics of non-alcoholic steatohepatitis among lean patients in Japan: Not uncommon and
not always benign. J Gastroenterol Hepatol 2019;34:1404-10.
87. Machado MV, Ferreira DM, Castro RE, et al. Liver and muscle in morbid obesity: the interplay of fatty liver and insulin resistance. PLoS
One 2012;7:e31738.
88. Bhanji RA, Narayanan P, Allen AM, Malhi H, Watt KD. Sarcopenia in hiding: the risk and consequence of underestimating muscle
dysfunction in nonalcoholic steatohepatitis. Hepatology 2017;66:2055-65.
89. Kalyani RR, Corriere M, Ferrucci L. Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases.
Lancet Diabetes Endocrinol 2014;2:819-29.
90. Hernandez-Alvarez MI, Thabit H, Burns N, et al. Subjects with early-onset type 2 diabetes show defective activation of the skeletal
muscle PGC-1{alpha}/Mitofusin-2 regulatory pathway in response to physical activity. Diabetes Care 2010;33:645-51.
91. Phillips T, Leeuwenburgh C. Muscle fiber specific apoptosis and TNF-alpha signaling in sarcopenia are attenuated by life-long calorie
restriction. FASEB J 2005;19:668-70.
92. Rubio-Ruiz ME, Guarner-Lans V, Perez-Torres I, Soto ME. Mechanisms underlying metabolic syndrome-related sarcopenia and possible
therapeutic measures. Int J Mol Sci 2019;20:647.
93. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.
Diabetes 2009;58:773-95.
94. Kim TN, Yang SJ, Yoo HJ, et al. Prevalence of sarcopenia and sarcopenic obesity in Korean adults: the Korean sarcopenic obesity study.
Int J Obes (Lond) 2009;33:885-92.
95. Bostrom P, Wu J, Jedrychowski MP, et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and
thermogenesis. Nature 2012;481:463-8.
96. Zhang HJ, Zhang XF, Ma ZM, et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol
2013;59:557-62.
97. Huh JY. The role of exercise-induced myokines in regulating metabolism. Arch Pharm Res 2018;41:14-29.
98. Han HQ, Zhou X, Mitch WE, Goldberg AL. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int J
Biochem Cell Biol 2013;45:2333-47.
99. Li F, Li Y, Duan Y, Hu CA, Tang Y, Yin Y. Myokines and adipokines: Involvement in the crosstalk between skeletal muscle and adipose
tissue. Cytokine Growth Factor Rev 2017;33:73-82.
100. Konopka AR, Wolff CA, Suer MK, Harber MP. Relationship between intermuscular adipose tissue infiltration and myostatin before and
after aerobic exercise training. Am J Physiol Regul Integr Comp Physiol 2018;315:R461-8.
101. Delogu W, Caligiuri A, Provenzano A, et al. Myostatin regulates the fibrogenic phenotype of hepatic stellate cells via c-jun N-terminal
kinase activation. Dig Liver Dis 2019;51:1400-8.
102. Garcia PS, Cabbabe A, Kambadur R, Nicholas G, Csete M. Brief-reports: elevated myostatin levels in patients with liver disease: a
potential contributor to skeletal muscle wasting. Anesth Analg 2010;111:707-9.
103. Nishikawa H, Enomoto H, Ishii A, et al. Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis.
J Cachexia Sarcopenia Muscle 2017;8:915-25.
104. Shida T, Oshida N, Oh S, Okada K, Shoda J. Progressive reduction in skeletal muscle mass to visceral fat area ratio is associated with a
worsening of the hepatic conditions of non-alcoholic fatty liver disease. Diabetes Metab Syndr Obes 2019;12:495-503.
105. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet
2008;40:1461-5.
106. Speliotes EK, Butler JL, Palmer CD, et al. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver
disease but not metabolic disease. Hepatology 2010;52:904-12.
107. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ, Nash CRN. The association of genetic variability in patatin-like phospholipase
domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010;52:894-903.
108. Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences
liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010;51:1209-17.
109. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3)
on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011;53:1883-94.
110. Liu YL, Patman GL, Leathart JB, et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic
fatty liver disease associated hepatocellular carcinoma. J Hepatol 2014;61:75-81.
111. Dubuquoy C, Robichon C, Lasnier F, et al. Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors
ChREBP and SREBP1c in mouse and human hepatocytes. J Hepatol 2011;55:145-53.
112. Huang Y, He S, Li JZ, et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A 2010;107:7892-7.
113. Hao L, Ito K, Huang KH, Sae-tan S, Lambert JD, Ross AC. Shifts in dietary carbohydrate-lipid exposure regulate expression of the